Patents by Inventor Jacqueline GIBBONS

Jacqueline GIBBONS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy
    Publication number: 20230042959
    Abstract: This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.
    Type: Application
    Filed: October 4, 2022
    Publication date: February 9, 2023
    Inventors: Jacqueline Gibbons, Joyce Mordenti, Michiel De Vries, Walter Krauwinkel, Taoufik Ouatas
  • Combination Therapy
    Publication number: 20210069166
    Abstract: This disclosure provides a dosage regimen for co-administration of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a strong CYP3A4 inducer.
    Type: Application
    Filed: March 30, 2020
    Publication date: March 11, 2021
    Inventors: Jacqueline Gibbons, Joyce Mordenti, Michiel De Vries, Walter Krauwinkel, Taoufik Ouatas
  • Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor
    Publication number: 20180235935
    Abstract: This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 23, 2018
    Inventors: Jacqueline GIBBONS, Joyce MORDENTI, Michiel DE VRIES, Walter KRAUWINKEL
  • Combination Therapy with Apalutamide
    Publication number: 20180228790
    Abstract: This disclosure provides a dosage regimen for co-administration of 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide and a strong CYP3A4 inducer.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 16, 2018
    Inventors: Jacqueline GIBBONS, Joyce MORDENTI, Michiel DE VRIES, Walter KRAUWINKEL
  • Specific diarylhydantoin and diarylthiohydantoin compounds
    Patent number: 9023879
    Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Medivation Prostate Therapeutics, Inc.
    Inventors: Rajendra Parasmal Jain, Jacqueline A. Gibbons
  • SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
    Publication number: 20130331421
    Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.
    Type: Application
    Filed: June 24, 2013
    Publication date: December 12, 2013
    Applicant: MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Rajendra Parasmal Jain, Jacqueline A. Gibbons
  • Specific diarylhydantoin and diarylthiohydantoin compounds
    Patent number: 8524755
    Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: September 3, 2013
    Assignee: Medivation Prostate Therapeutics, Inc.
    Inventors: Rajendra Parasmal Jain, Jacqueline A. Gibbons
  • SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
    Publication number: 20120035231
    Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.
    Type: Application
    Filed: February 24, 2010
    Publication date: February 9, 2012
    Inventors: Rajendra Parasmal Jain, Jacqueline A. Gibbons
  • ADME analysis of mixtures
    Patent number: 5989918
    Abstract: A method for analyzing the ADME/PK properties of a mixture of compounds is (1) perfusing an animal or organ with a perfluorocarbon emulsion blood substitute, (2) administering the mixture of test compounds, (3) withdrawing an aliquot of the perfusate, (4) disrupting the emulsion, and (5) analyzing the aqueous phase of the perfusate for the concentration of test compounds.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: November 23, 1999
    Assignee: Chiron Corporation
    Inventors: Corine M. Dietz, Jacqueline A. Gibbons, Eric W. Taylor